Related Experiment Videos
[Clinical studies on pivmecillinam in urinary tract infections (author's transl)]
Abstract:
Pivmecillinam (PMPC), semisynthetic penicillin for oral use, was studied clinically and following results were obtained. 1) Twenty-eight patients with acute simple cystitis treated with the drug 200 mg/day for 4 days, clinical results were excellent in 23 cases and moderate in 5 cases. Six patients with chronic simple cystitis treated with the drug 400 mg/day for 7 days, clinical results were excellent in 4 cases, moderate in 1 case and poor in 1 case. Eight patients with complicated urinary tract infections treated with the drug 400 mg/day for 7 days, clinical results were excellent in 2 cases, moderate in 2 cases and poor in 4 cases. Overall effectiveness amounted to 88.1%. 2) Pivmecillinam was clinically effective in patients infected by Gram-negative bacteria except Pseudomonas aeruginosa. 3) No side effects were observed in all cases. The effectiveness of PMPC for acute simple cystitis was compared with that of talampicillin (TAPC), ampicillin (ABPC), amoxicillin (AMPC) and pivampicillin (PVPC) reported previously and PMPC was assessed as the most useful agent in these. Then, pivmecillinam should be chosen firstly as a chemotherapeutic agent for acute simple cystitis.
Insights
Pivmecillinam (PMPC) effectively treats acute simple cystitis with an 88.1% overall success rate and no observed side effects. This oral penicillin is a leading choice for urinary tract infections caused by Gram-negative bacteria, excluding Pseudomonas aeruginosa.
Area of Science:
- Pharmacology
- Urology
- Infectious Diseases
Background:
- Urinary tract infections (UTIs) are common, with bacterial pathogens frequently causing cystitis.
- Effective antibiotic therapy is crucial for managing UTIs, particularly simple cystitis.
- Pivmecillinam (PMPC) is an oral semisynthetic penicillin antibiotic.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of pivmecillinam (PMPC) in patients with acute and chronic simple cystitis, and complicated urinary tract infections.
- To compare the effectiveness of PMPC with other oral penicillins for acute simple cystitis.
Main Methods:
- Clinical assessment of PMPC in patients with various forms of UTIs.
- Dosage regimens included 200 mg/day for 4 days for acute simple cystitis and 400 mg/day for 7 days for chronic cystitis and complicated UTIs.
- Bacterial susceptibility testing focused on Gram-negative bacteria, excluding Pseudomonas aeruginosa.
Main Results:
- Overall effectiveness of PMPC was 88.1%.
- Excellent or moderate clinical results were observed in 23/28 patients with acute simple cystitis and 4/6 with chronic simple cystitis.
- PMPC demonstrated effectiveness against Gram-negative bacteria, excluding Pseudomonas aeruginosa, with no reported side effects.
Conclusions:
- Pivmecillinam (PMPC) is a highly effective and safe oral antibiotic for treating acute simple cystitis.
- PMPC is a preferred chemotherapeutic agent for acute simple cystitis compared to talampicillin, ampicillin, amoxicillin, and pivampicillin.
- The drug shows promise for UTIs caused by susceptible Gram-negative bacteria.